الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Malignant lymphoma is the most common hematological malignancy, it accounts for approximately 8% of all adult malignancies. Lymphoid neoplasms are divided into Hodgkin disease (HD) and non-Hodgkin’s lymphoma (NHL). Hodgkin lymphoma accounts for less than 1% of all cases of cancer, Non- Hodgkin lymphoma accounts for about 5% of all cases of cancer. Non-Hodgkin lymphoma forms the vast majority of cases and has a greater predilection to disseminate to extra-nodal sites. Thoracic lymphomas are characterized by enlargement of mediastinal lymph nodes, parenchymal abnormalities, pleural, pericardial and chest wall involvement. Intra-thoracic disease is observed in about 70–85% of Hodgkin’s disease patients and in 25–50% of those with Non-Hodgkin’s lymphoma PETCT provides the needed information about both the metabolic activity as well the anatomical location of the neoplasm combining the advantages of both Nuclear medicine techniques provide unique physiologic information about malignancies, including lymphomas. Positron emission tomography (PET) provides metabolic information that has been documented to be useful in patient care. The wide array of positron-emitting radiopharmaceuticals has been used to characterize multiple physiologic and pathologic states. The major utilization of PET clinically is in oncology and consists of imaging the distribution of fluorine 18 fluorodeoxyglucose (FDG), an analogue of glucose that accumulates in most tumors in a greater amount than it does in normal tissue. FDG PET is being used in diagnosis, staging, restaging and follow-up of Hodgkin and Non-Hodgkin lymphomas.